Companies: 10,795·Total market cap: $144.5T
Genus plc

Genus plc

GENSFOTCHealthcare● Active
$31.07
+$0.00(+0.00%)
Market Cap$2.1B
P/E Ratio—
52W High$37.25
52W Low$26.01
Overview

Genus plc (GENSF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

GENSF · cash on hand · updated Jun 30, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$48.0M▲ +12.9% vs prior year
FY · as of Jun 30, 2025 · Reported in GBP
Cash & Cash Equiv. (CCE)
$48.0M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
+12.9%
vs prior fiscal year
Latest Quarter
$43.4M
Q4 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in GBP

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: June 30, 2025

Net cash vs debt

Cash & ST Investments$48.0MCash on Hand
Total Debt$265.9MTotal Debt
Net Cash / Net Debt−$217.9MNet Debt Position
Cash vs Debt Ratio
Cash 15%Debt 85%

Genus plc carries a net debt position of $217.9M. Total debt ($265.9M) exceeds cash on hand ($48.0M). Genus plc cash vs debt ratio: 15% cash / 85% debt.

Net Cash = Cash & ST Investments − Total Debt$48.0M − $265.9M = −$217.9M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
GENSF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Jun 30, 2025Latest$48.0M+12.9%
Jun 30, 2024$42.5M+17.1%
Jun 30, 2023$36.3M-6.4%
Jun 30, 2022$38.8M-15.7%
Jun 30, 2021$46.0M+11.4%
GENSF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.5%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.5%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Genus plc
Genus plcYOU
GENSF
$48.0M2.3%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Genus plc (GENSF) cash on hand as of June 30, 2025 is $48.0M, comprising $48.0M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Genus plc cash and short-term investments on the balance sheet (10-K filing). Also referred to as Genus plc cash reserves or cash position.

Genus plc annual cash on hand history shows increased +12.9% in 2025: increased +12.9% in 2025. Genus plc cash reserves in 2025 reflect the company's capital allocation strategy.

Genus plc carries total debt of $265.9M against cash of $48.0M, resulting in a net debt position of -$217.9M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

GENSF cash on hand · 5 questions

As of June 30, 2025, Genus plc (GENSF) has $48,000,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $48,000,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (December 31, 2025): $43,392,967. Data sourced from the annual 10-K filing via FMP.

GENSF cash on handGENSF cash reservesGENSF cash 2025how much cash does GENSF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Genus plc · Genus plc SEC 10-K & 10-Q filings · US GAAP · Last updated: June 30, 2025